MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/130/0.1/20.12.24 Stock

Warrant

DE000ME1GBE4

Real-time Bid/Ask 13:10:09 2024-07-01 EDT
2.22 EUR / 2.23 EUR +6.97% Intraday chart for MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/130/0.1/20.12.24
Current month+40.54%
1 month+38.67%
Date Price Change
24-07-01 2.04 -1.92%
24-06-28 2.08 -1.89%
24-06-27 2.12 0.00%
24-06-26 2.12 -7.83%
24-06-25 2.3 +17.35%

Delayed Quote Börse Stuttgart

Last update July 01, 2024 at 08:50 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying NOVO NORDISK A/S
Issuer Morgan Stanley
WKN ME1GBE
ISINDE000ME1GBE4
Date issued 2023-10-03
Strike 130 $
Maturity 2024-12-20 (172 Days)
Parity 10 : 1
Emission price 0.36
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 2.3
Lowest since issue 0.27
Delta0.76x
Omega 4.644
Premium5.44x
Gearing6.14x
Moneyness 1.122
Difference Strike -15.71 $
Difference Strike %-12.08%
Spread 0.01
Spread %0.45%
Theoretical value 2.215
Implied Volatility 33.45 %
Total Loss Probability 31.64 %
Intrinsic value 1.476
Present value 0.7388
Break even 153.77 €
Theta-0.03x
Vega0.03x
Rho0.04x

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
More about the company

Ratings for Novo Nordisk A/S

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Consensus: Novo Nordisk A/S

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006 DKK
Average target price
949.7 DKK
Spread / Average Target
-5.56%
Consensus